Skip to main content

Lodine XL Side Effects

Generic name: etodolac

Medically reviewed by Drugs.com. Last updated on Nov 20, 2023.

Note: This document contains side effect information about etodolac. Some dosage forms listed on this page may not apply to the brand name Lodine XL.

Applies to etodolac: oral capsule, oral tablet, oral tablet extended release.

Warning

Oral route (Tablet; Capsule; Tablet, Extended Release)

NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may be increased in patients with cardiovascular disease or risk factors for cardiovascular disease. Etodolac is contraindicated for the treatment of perioperative pain in the setting of CABG surgery. NSAIDs can also cause an increased risk of serious gastrointestinal adverse events especially in the elderly, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.

Serious side effects of Lodine XL

Along with its needed effects, etodolac (the active ingredient contained in Lodine XL) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking etodolac:

More common

Symptoms of overdose

Other side effects of Lodine XL

Some side effects of etodolac may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to etodolac: oral capsule, oral tablet, oral tablet extended release.

General

The most frequently reported side effects were gastrointestinal in nature and included dyspepsia, abdominal pain, constipation, diarrhea, dyspepsia, flatulence, gross bleeding/perforation, heartburn, nausea, gastric ulcers, duodenal ulcers, and vomiting.[Ref]

Gastrointestinal

Very common (10% or more): Dyspepsia (10%)

Common (1% to 10%): Abdominal pain, constipation, diarrhea, dyspepsia, flatulence, gross bleeding/perforation, heartburn, nausea, gastric ulcer, duodenal ulcer, vomiting, abdominal distention, epigastric pain, stools abnormal, gastritis, melena

Very rare (less than 0.01%): Pancreatitis

Frequency not reported: Dry mouth, ulcerative stomatitis, eructation, peptic ulcer, gastrointestinal (GI) bleeding, perforation, esophagitis, esophageal stricture, cardiospasm, colitis, GI discomfort, burning sensation, gastralgia, upper abdominal discomfort, glossitis, hematemesis, rectal bleeding, heartburn, indigestion, ulcerative colitis exacerbated, Crohn's disease exacerbated

Postmarketing reports: Intestinal ulceration[Ref]

Cardiovascular

Frequency not reported: Hypertension, congestive heart failure, flushing, palpitations, arrhythmia, myocardial infarction, tachycardia, cardiac failure

Postmarketing reports: Necrotizing vasculitis[Ref]

Renal

Common (1% to 10%): Renal function abnormal

Frequency not reported: Renal calculus, interstitial nephritis, renal impairment, nephrotoxicity, nephrotic syndrome, renal failure

Postmarketing reports: Renal insufficiency, renal papillary necrosis[Ref]

Nervous system

Common (1% to 10%): Dizziness, headache

Frequency not reported: Syncope, somnolence, cerebrovascular accident, paresthesia, taste perversion, loss of taste, convulsion, coma, tremor, drowsiness, optic neuritis, stroke[Ref]

Dermatologic

Common (1% to 10%): Pruritus, rash

Very rare (less than 0.01%): Stevens-Johnson Syndrome, toxic epidermal necrolysis

Frequency not reported: Ecchymosis, angioedema, sweating, urticaria, exfoliative dermatitis, vesiculobullous rash, hyperpigmentation, alopecia, maculopapular rash, photosensitivity, skin peeling, purpura, erythema multiforme

Postmarketing reports: Allergic vasculitis, cutaneous vasculitis, leukocytoclastic vasculitis[Ref]

Hepatic

Common (1% to 10%): Liver enzymes increased

Frequency not reported: Bilirubinuria, hepatitis, jaundice

Postmarketing reports: Cholestatic hepatitis, hepatitis, cholestatic jaundice, duodenitis, hepatic failure, liver necrosis, fatal fulminant hepatitis[Ref]

Hematologic

Common (1% to 10%): Anemia, bleeding time increased

Frequency not reported: Thrombocytopenia, lymphadenopathy, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, pancytopenia, leukopenia[Ref]

Metabolic

Frequency not reported: Anorexia

Postmarketing reports: Hyperglycemia[Ref]

Psychiatric

Common (1% to 10%): Depression, nervousness

Frequency not reported: Insomnia, confusion, anxiety, dreams abnormal, hallucination, disorientation[Ref]

Genitourinary

Common (1% to 10%): Dysuria, urinary frequency

Frequency not reported: Cystitis, hematuria, leukorrhea, uterine bleeding irregular, oliguria, polyuria, proteinuria[Ref]

Ocular

Common (1% to 10%): Vision blurred

Frequency not reported: Photophobia, transient visual disturbance, conjunctivitis[Ref]

Respiratory

Frequency not reported: Asthma/aggravated asthma, bronchitis, bronchospasm, dyspnea, pharyngitis, rhinitis, sinusitis, respiratory depression, pneumonia

Postmarketing reports: Pulmonary infiltration eosinophilic[Ref]

Musculoskeletal

Common (1% to 10%): Arthralgia

Frequency not reported: Muscle pain[Ref]

Other

Common (1% to 10%): Edema, tinnitus, fever, chills, asthenia, malaise, fatigue

Frequency not reported: Serum creatinine increased, infection, weight abnormal, irritability, deafness, meningitis, vertigo, sepsis, death, weakness, aseptic meningitis

Postmarketing reports: Thirst, BUN increased[Ref]

Immunologic

Frequency not reported: Allergic/hypersensitivity reaction, anaphylactic/anaphylactoid reaction[Ref]

References

1. Product Information. Lodine (etodolac). Wyeth-Ayerst Laboratories. 2001;PROD.

2. Cerner Multum, Inc. UK Summary of Product Characteristics.

3. Product Information. Etodolac ER (etodolac). Taro Pharmaceuticals U.S.A. Inc. 2016.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.